Company
Lexicon Pharmaceuticals, Inc.
Headquarters: The Woodlands, TX, United States
Founded: The Woodlands, TX, 1995
Employees: 87
CEO: Mr. Lonnel Coats
Market Cap
$603.7 Million
USD as of July 1, 2024
Lexicon Pharmaceuticals, Inc. Categories
United States Healthcare BiotechnologyUnited States Healthcare United States Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $121.36 B |
| Regeneron Pharmaceuticals, Inc. | $115.11 B |
| CSL Limited | $95.75 B |
| Marinomed Biotech AG | $75.67 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
Lexicon Pharmaceuticals, Inc. has the following listings and related stock indices.
Stock: NASDAQ: LXRX wb_incandescent
Stock: FSX: LX31 wb_incandescent
Key People
Lonnel Coats, president and chief executive officer Brian P. Zambrowicz, E VP & Chief Scientific Officer Jeffrey L. Wade, E VP of Corporate Development & Chief Scientific Officer Alan J. Main, E VP of Pharmaceutical Research Pablo Lapuerta, E VP of Clinical Development & Chief Medical Officer James F. Tessmer, VP of Finance and Accounting
Financials
Revenue: $324.1 Million(2019)